Nektar, Bristol-Myers Amend Collaboration for Bempeg Plus Opdivo
January 10 2020 - 7:56AM
Dow Jones News
By Michael Dabaie
Nektar Therapeutics (NKTR) and Bristol-Myers Squibb Co. (BMY)
said Friday they have agreed to a new joint development plan for
bempegaldesleukin plus Opdivo, or nivolumab, in multiple new
registrational trials.
With the revision to the companies' strategic collaboration
agreement, Nektar and Bristol-Myers Squibb will expand the active
clinical development program from three ongoing registrational
trials--in first-line metastatic melanoma, first-line
cisplatin-ineligible metastatic urothelial cancer and first-line
metastatic renal cell carcinoma--to include two additional
registrational trials in adjuvant melanoma and in muscle-invasive
bladder cancer.
The companies said they also will initiate a Phase 1/2 dose
study to evaluate bempeg plus nivolumab in combination with
axitinib in first-line RCC in order to support a future
registrational trial.
The companies will share costs for these studies.
Bristol-Myers Squibb will also independently conduct and fund a
Phase 1/2 dose optimization and expansion study in first-line
non-small-cell lung cancer with bempeg and nivolumab.
Nektar is eligible to receive a $25.0 million milestone payment
in connection with the registrational adjuvant melanoma trial,
$25.0 million in connection with the registrational muscle-invasive
bladder cancer trial and $75.0 million in a registrational
first-line non-small-cell lung cancer trial, the companies said in
a Securities and Exchange Commission filing.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
January 10, 2020 07:41 ET (12:41 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024